Evidence map›Paper›PMID 34359631›Full record

ArticleCancers2021

The Human Fetal and Adult Stem Cell Secretome Can Exert Cardioprotective Paracrine Effects against Cardiotoxicity and Oxidative Stress from Cancer Treatment.

Federico Villa, Silvia Bruno, Ambra Costa, Mingchuan Li, Michele Russo, James Cimino, Paola Altieri, Clarissa Ruggeri, Cansu Gorgun, Pierangela De Biasio and 8 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 1 country.

Federico VillaCellular Oncology Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.
Silvia BrunoDepartment of Experimental Medicine (DIMES), University of Genova, 16132 Genova, Italy.
Ambra CostaDepartment of Experimental Medicine (DIMES), University of Genova, 16132 Genova, Italy.
Mingchuan LiDepartment of Molecular Biotechnology and Health Sciences, University of Torino, 10126 Torino, Italy.
Michele RussoDepartment of Molecular Biotechnology and Health Sciences, University of Torino, 10126 Torino, Italy.
James CiminoDepartment of Molecular Biotechnology and Health Sciences, University of Torino, 10126 Torino, Italy.
Paola AltieriLaboratory of Cardiovascular Biology, Department of Internal Medicine (DIMI), University of Genova, 16132 Genova, Italy.
Clarissa RuggeriLaboratory of Cardiovascular Biology, Department of Internal Medicine (DIMI), University of Genova, 16132 Genova, Italy.
Cansu GorgunCellular Oncology Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.ORCID 0000-0002-0460-2952
Pierangela De BiasioUnit of Prenatal Diagnosis and Perinatal Medicine, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.
Dario PaladiniFetal Medicine and Surgery Unit, IRCCS Istituto Giannina Gaslini, 16147 Genova, Italy.
Domenico CovielloHuman Genetics Laboratory, IRCCS Istituto Giannina Gaslini, 16147 Genova, Italy.ORCID 0000-0001-8440-865X
Rodolfo QuartoCellular Oncology Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.ORCID 0000-0002-1146-894X
Pietro AmeriLaboratory of Cardiovascular Biology, Department of Internal Medicine (DIMI), University of Genova, 16132 Genova, Italy.
Alessandra GhigoDepartment of Molecular Biotechnology and Health Sciences, University of Torino, 10126 Torino, Italy.ORCID 0000-0002-1193-5296
Silvia RaveraDepartment of Experimental Medicine (DIMES), University of Genova, 16132 Genova, Italy.ORCID 0000-0002-0803-1042
Roberta TassoCellular Oncology Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.
Sveva BolliniDepartment of Experimental Medicine (DIMES), University of Genova, 16132 Genova, Italy.ORCID 0000-0003-1076-0823
Ospedale Policlinico San Martino · ITUniversity of Genoa · ITUniversity of Turin · ITIstituto Giannina Gaslini · IT

Funding

Italian Ministry of Health Young Investigator Grant-GR-2013-02357519University of Genova, Genova, Italy "Curiosity Driven" grant: Triggering CARDIOmyocyte renewal by harnessing STem cell pARacrine potential (CARDIO-STAR)
6 · The paper itself

Abstract

Cardiovascular side effects are major shortcomings of cancer treatments causing cardiotoxicity and late-onset cardiomyopathy. While doxorubicin (Dox) has been reported as an effective chemotherapy agent, unspecific impairment in cardiomyocyte mitochondria activity has been documented. We demonstrated that the human fetal amniotic fluid-stem cell (hAFS) secretome, namely the secreted paracrine factors within the hAFS-conditioned medium (hAFS-CM), exerts pro-survival effects on Dox-exposed cardiomyocytes. Here, we provide a detailed comparison of the cardioprotective potential of hAFS-CM over the secretome of mesenchymal stromal cells from adipose tissue (hMSC-CM). hAFS and hMSC were preconditioned under hypoxia to enrich their secretome. The cardioprotective effects of hAFS/hMSC-CM were evaluated on murine neonatal ventricular cardiomyocytes (mNVCM) and on their fibroblast counterpart (mNVFib), and their long-term paracrine effects were investigated in a mouse model of Dox-induced cardiomyopathy. Both secretomes significantly contributed to preserving mitochondrial metabolism within Dox-injured cardiac cells. hAFS-CM and hMSC-CM inhibited body weight loss, improved myocardial function, reduced lipid peroxidation and counteracted the impairment of mitochondrial complex I activity, oxygen consumption, and ATP synthesis induced by Dox. The hAFS and hMSC secretomes can be exploited for inhibiting cardiotoxic detrimental side effects of Dox during cancer therapy, thus ensuring cardioprotection via combinatorial paracrine therapy in association with standard oncological treatments.

Indexed as

cancer treatmentcardiomyocytecardiotoxicitydoxorubicinmitochondriaoxidative stressparacrine effectstem cell

Identifiers

PMID34359631
PMCPMC8345068
OpenAlexW3184131101

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.